Soxataltinib, a highly selective CNS-penetrant RET inhibitor demonstrates durable activity in RET fusion–positive non-small cell lung cancer phase 2 study

Journal of Thoracic Oncology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles